What is claimed is:

1. An isolated recombinant monoclonal antibody or antigen-binding fragment thereof that specifically binds to ZIKA virus (ZIKV) and/or a ZIKV envelope glycoprotein (E), wherein the antibody or antigen-binding fragment thereof neutralizes ZIKV *in vitro* with an IC_{50} less than or equal to about 10^{-9}M and wherein the antibody or antigen-binding fragment thereof demonstrates a protective effect *in vivo* in a ZIKV infected animal.

2. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1, wherein the antibody comprises the three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) contained within any one of the heavy chain variable region (HCVR) sequences selected from the group consisting of SEQ ID NOs: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 226, 242, 258, 274, 290, 306, 322 and 338; and the three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) contained within any one of the light chain variable region (LCVR) sequences selected from the group consisting of SEQ ID NOs: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282, 298, 314, 330 and 346.

3. The isolated monoclonal antibody or antigen-binding fragment thereof of either claim 1 or claim 2, comprising a HCVR having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 226, 242, 258, 274, 290, 306, 322 and 338.

4. The isolated monoclonal antibody or antigen-binding fragment thereof of any one of claims 1-3, comprising a LCVR having an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282, 298, 314, 330 and 346.

5. The isolated monoclonal antibody or antigen-binding fragment thereof of any one of claims 1-4, comprising:

(a) a HCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 20, 36, 52, 68, 84, 100, 116, 132, 148, 164, 180, 196, 212, 228, 244, 260, 276, 292, 308, 324 and 340;

(b) a HCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 22, 38, 54, 70, 86, 102, 118, 134, 150, 166, 182, 198, 214, 230, 246, 262, 278, 294, 310, 326 and 342;

(c) a HCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 8, 24, 40, 56, 72, 88, 104, 120, 136, 152, 168, 184, 200, 216, 232, 248, 264, 280, 296, 312, 328 and 344;

(d) a LCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 12, 28, 44, 60, 76, 92, 108, 124, 140, 156, 172, 188, 204, 220, 236, 252, 268, 284, 300, 316, 332 and 348;

(e) a LCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 14, 30, 46, 62, 78, 94, 110, 126, 142, 158, 174, 190, 206, 222, 238, 254, 270, 286, 302, 318, 334 and 350;

(f) a LCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 16, 32, 48, 64, 80, 96, 112, 128, 144, 160, 176, 192, 208, 224, 240, 256, 272, 288, 304, 320, 336 and 352.

6. The isolated monoclonal antibody or antigen-binding fragment of any one of claims 1-5, comprising a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10, 18/26, 34/42, 50/58, 66/74, 82/90, 98/106, 114/122, 130/138, 146/154, 162/170, 178/186, 194/202, 210/218, 226/234, 242/250, 258/266, 274/282, 290/298, 306/314, 322/330 and 338/346.

7. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 5, comprising an HCDR1 amino acid sequence of SEQ ID NO: 116; an HCDR2 amino acid sequence of SEQ ID NO: 118; an HCDR3 amino acid sequence of SEQ ID NO: 120; an LCDR1 amino acid sequence of SEQ ID NO: 124; an LCDR2 amino acid sequence of SEQ ID NO: 126 and an LCDR3 amino acid sequence of SEQ ID NO: 128.

8. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 5, comprising an HCDR1 amino acid sequence of SEQ ID NO: 260; an HCDR2 amino acid sequence of SEQ ID NO: 262; an HCDR3 amino acid sequence of SEQ ID NO: 264; an

LCDR1 amino acid sequence of SEQ ID NO: 268; an LCDR2 amino acid sequence of SEQ ID NO: 270 and an LCDR3 amino acid sequence of SEQ ID NO: 272.

9. The isolated monoclonal antibody or antigen-binding fragment thereof of any one of claims 1-8, whereby the antibody further comprises an Fc domain having the amino acid sequence of SEQ ID NO: 357.

10. The isolated monoclonal antibody or antigen-binding fragment thereof of any one of claims 1-9, wherein the antibody or antigen-binding fragment thereof does not contribute to Antibody Dependent Enhancement (ADE).

11. The isolated monoclonal antibody or antigen-binding fragment of any one of claims 2-10, having one or more of the following characteristics:

(a) is a fully human monoclonal antibody;

(b) binds to a VLP expressing ZIKV prM/E with an EC_{50} ranging from about 80pM to about 150nM;

(c) binds to ZIKV E with a dissociation constant (K_D) of less than 10^{-7}M, as measured in a surface plasmon resonance assay; or

(d) may or may not demonstrate a change in dissociative half-life (t½) at pH 5 or pH 6 relative to pH 7.4.

12. An isolated monoclonal antibody or antigen-binding fragment thereof that competes for binding to ZIKV and/or ZIKV E with a reference antibody or antigen-binding fragment comprising the CDRs of a HCVR, wherein the HCVR has an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 226, 242, 258, 274, 290, 306, 322 and 338; and the CDRs of a LCVR, wherein the LCVR has an amino acid sequence selected from the group consisting SEQ ID NOs: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282, 298, 314, 330 and 346.

13. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to the same epitope on ZIKV and/or ZIKV E as a reference antibody or antigen-binding fragment comprising the CDRs of a HCVR, wherein the HCVR has an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162,

178, 194, 210, 226, 242, 258, 274, 290, 306, 322 and 338; and the CDRs of a LCVR, wherein the LCVR has an amino acid sequence selected from the group consisting SEQ ID NOs: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282, 298, 314, 330 and 346.

14. Use of one or more anti-ZIKV antibodies or antigen-binding fragments thereof of any one of claims 1-11 in the manufacture of a medicament for neutralizing infectious ZIKV by enhancing protection of the cell from virus infection, or from cell death.

15. The use of claim 14, wherein the one or more anti-ZIKV antibodies or antigen-binding fragments thereof neutralize infectious ZIKV having a wild type E protein, wherein the wild type E protein has a serine at position 302 of SEQ ID NO: 376, a threonine at position 311 of SEQ ID NO: 376, and a lysine at position 369 of SEQ ID NO: 376, but will not neutralize an infectious ZIKV having a mutated form of the E protein, wherein the mutated form of the E protein contains one or more of the following changes: a phenylalanine at position 302 of SEQ ID NO: 376, an isoleucine at position 311 of SEQ ID NO: 376, or a glutamic acid at position 369 of SEQ ID NO: 376.

16. The use of claim 14, wherein the enhanced protection is observed when the antibody is used alone, or when it is used in combination with one or more additional therapeutic agents or anti-ZIKV treatment modalities, wherein the one or more additional therapeutic agents is selected from the group consisting of an anti-viral drug, an anti-inflammatory drug (*e.g.* corticosteroids and non-steroidal anti-inflammatory drugs), one or more different anti-ZIKV antibodies, a vaccine for ZIKV, an immunomodulator and an interferon.

17. The use of claim 16, wherein the one or more different anti-ZIKV antibodies comprise a heavy chain variable region (HCVR) and a light chain variable region (LCVR) amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10, 18/26, 34/42, 50/58, 66/74, 82/90, 98/106, 114/122, 130/138, 146/154, 162/170, 178/186, 194/202, 210/218, 226/234, 242/250, 258/266, 274/282, 290/298, 306/314, 322/330 and 338/346.

18. A pharmaceutical composition comprising one or more isolated monoclonal antibodies or antigen-binding fragments thereof that bind specifically to ZIKV according to any one of claims 1-11, and a pharmaceutically acceptable carrier or diluent.

19. The pharmaceutical composition of claim 18, wherein the one or more isolated monoclonal antibodies tor antigen-binding fragments thereof that bind specifically to ZIKV comprise the three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) contained within any one of the heavy chain variable region (HCVR) sequences selected from the group consisting of SEQ ID NOs: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 226, 242, 258, 274, 290, 306, 322 and 338; and the three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) contained within any one of the light chain variable region (LCVR) sequences selected from the group consisting of SEQ ID NOs: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282, 298, 314, 330 and 346.

20. The pharmaceutical composition of either one of claim 18 or claim 19, wherein the one or more isolated monoclonal antibodies that bind specifically to ZIKV comprise an HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10, 18/26, 34/42, 50/58, 66/74, 82/90, 98/106, 114/122, 130/138, 146/154, 162/170, 178/186, 194/202, 210/218, 226/234, 242/250, 258/266, 274/282, 290/298, 306/314, 322/330 and 338/346.

21. The pharmaceutical composition of any one of claims 18-20, wherein the one or more isolated monoclonal antibodies that bind specifically to ZIKV comprise an HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 66/74, 114/122 and 258/266.

22. The pharmaceutical composition of claim 21, wherein the one or more isolated monoclonal antibodies that bind specifically to ZIKV comprise an HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 114/122 and 258/266.

23. The pharmaceutical composition of any one of claims 18-22, wherein the one or more isolated monoclonal antibodies that bind specifically to ZIKV comprise:

a) an isolated first monoclonal antibody, or antigen-binding fragment thereof that binds specifically to ZIKV, comprising a HCDR1 having the amino acid sequence of SEQ ID NO: 116, a HCDR2 having the amino acid sequence of SEQ ID NO: 118, a HCDR3 having the amino acid sequence of SEQ ID NO: 120, a LCDR1 having the amino acid sequence of SEQ ID NO: 124, a LCDR2 having the amino acid sequence of SEQ ID NO: 126, a LCDR3 having the

amino acid sequence of SEQ ID NO: 128;

b) an isolated second monoclonal antibody, or antigen-binding fragment thereof that binds specifically to ZIKV, comprising a HCDR1 having the amino acid sequence of SEQ ID NO: 260, a HCDR2 having the amino acid sequence of SEQ ID NO: 262, a HCDR3 having the amino acid sequence of SEQ ID NO: 264, a LCDR1 having the amino acid sequence of SEQ ID NO: 268, a LCDR2 having the amino acid sequence of SEQ ID NO: 270, a LCDR3 having the amino acid sequence of SEQ ID NO: 272; and

c) a pharmaceutically acceptable carrier or diluent.

24. The pharmaceutical composition of any one of claims 18-23, wherein the one or more anti-ZIKV antibodies neutralize one or more ZIKV strains selected from the group consisting of MR766 (Uganda 1947), PRVABC59 (Puerto Rico 2015) and FLR (Colombia 2015) strains.

25. A pharmaceutical composition comprising at least two isolated monoclonal antibodies or antigen-binding fragments thereof that bind specifically to ZIKV, and a pharmaceutically acceptable carrier or diluent, wherein at least one of the two monoclonal antibodies neutralizes ZIKV *in vitro* with an IC_{50} less than about 10^{-9}M and demonstrates a protective effect *in vivo* in a ZIKV infected animal.

26. The pharmaceutical composition of claim 25, wherein the composition comprises (a) a first anti-ZIKV monoclonal antibody or an antigen-binding fragment thereof; (b) a second anti-ZIKV monoclonal antibody or antigen-binding fragment thereof; wherein the first antibody binds to, or interacts with, a first epitope on ZIKV and the second antibody binds to, or interact(s) with a second different epitope on ZIKV, and (c) a pharmaceutically acceptable carrier or diluent.

27. The pharmaceutical composition of either one of claim 25 or claim 26, wherein the first and second anti-ZIKV monoclonal antibodies or antigen-binding fragments thereof comprise the three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) contained within any one of the heavy chain variable region (HCVR) sequences selected from the group consisting of SEQ ID NOs: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 226, 242, 258, 274, 290, 306, 322 and 338; and the three light chain

complementarity determining regions (LCDR1, LCDR2 and LCDR3) contained within any one of the light chain variable region (LCVR) sequences selected from the group consisting of SEQ ID NOs: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282, 298, 314, 330 and 346.

28. The pharmaceutical composition of any one of claims 25-27, wherein:

a) the first anti-ZIKV monoclonal antibody or antigen-binding fragment thereof comprises a HCDR1 having the amino acid sequence of SEQ ID NO: 116, a HCDR2 having the amino acid sequence of SEQ ID NO: 118, a HCDR3 having the amino acid sequence of SEQ ID NO: 120, a LCDR1 having the amino acid sequence of SEQ ID NO: 124, a LCDR2 having the amino acid sequence of SEQ ID NO: 126, and a LCDR3 having the amino acid sequence of SEQ ID NO: 128; and wherein

b) the second anti-ZIKV monoclonal antibody, or antigen-binding fragment thereof that binds specifically to ZIKV, comprises a HCDR1 having the amino acid sequence of SEQ ID NO: 260, a HCDR2 having the amino acid sequence of SEQ ID NO: 262, a HCDR3 having the amino acid sequence of SEQ ID NO: 264, a LCDR1 having the amino acid sequence of SEQ ID NO: 268, a LCDR2 having the amino acid sequence of SEQ ID NO: 270, and a LCDR3 having the amino acid sequence of SEQ ID NO: 272.

29. The pharmaceutical composition of any one of claims 25-28, wherein the at least two anti-ZIKV antibodies that bind specifically to ZIKV comprise an HCVR/LCVR amino acid sequence pair of SEQ ID NOs: 114/122 and SEQ ID NOs: 258/266.

30. The pharmaceutical composition of any one of claims 25-29, wherein the at least two anti-ZIKV antibodies neutralize one or more ZIKV strains selected from the group consisting of MR766 (Uganda 1947), PRVABC59 (Puerto Rico 2015) and FLR (Colombia 2015) strains.

31. A pharmaceutical composition comprising a first isolated monoclonal antibody or an antigen-binding fragment thereof that binds specifically to ZIKV, wherein the first isolated monoclonal antibody or an antigen-binding fragment thereof comprises an HCDR1 amino acid sequence of SEQ ID NO: 116; an HCDR2 amino acid sequence of SEQ ID NO: 118; an HCDR3 amino acid sequence of SEQ ID NO: 120; an LCDR1 amino acid sequence of SEQ

ID NO: 124; an LCDR2 amino acid sequence of SEQ ID NO: 126 and an LCDR3 amino acid sequence of SEQ ID NO: 128, and a pharmaceutically acceptable carrier or diluent.

32. The pharmaceutical composition of claim 31, further comprising a second isolated monoclonal antibody or an antigen-binding fragment thereof that binds specifically to ZIKV, wherein the second isolated monoclonal antibody or an antigen-binding fragment thereof comprises an HCDR1 amino acid sequence of SEQ ID NO: 260; an HCDR2 amino acid sequence of SEQ ID NO: 262; an HCDR3 amino acid sequence of SEQ ID NO: 264; an LCDR1 amino acid sequence of SEQ ID NO: 268; an LCDR2 amino acid sequence of SEQ ID NO: 270 and an LCDR3 amino acid sequence of SEQ ID NO: 272.

33. An isolated nucleic acid molecule encoding a monoclonal antibody, or a fragment thereof that binds specifically to ZIKV according to any one of claims 1-11.

34. A vector comprising the nucleic acid molecule of claim 33.

35. An isolated cell expressing the vector of claim 34.

36. Use of one or more anti-ZIKV antibodies or antigen-binding fragments thereof of any one of claims 1-11 in the manufacture of a medicament for preventing, treating or ameliorating at least one symptom of ZIKV infection, or of decreasing the frequency or severity of at least one symptom of ZIKV infection in a subject in need thereof.

37. The use of claim 36, wherein the one or more anti-ZIKV antibodies comprise the HCVR/LCVR amino acid sequence pairs of SEQ ID NOs: 114/122 and 258/266.

38. The use of claim 37, wherein the at least one symptom is selected from the group consisting of fever, headache, arthralgia, myalgia and a maculopapular rash.

39. The use of claim 36, wherein the medicament is for administration prophylactically or therapeutically to the subject in need thereof.

40. The use of claim 36, wherein the subject in need thereof is at risk for exposure to, or for acquiring a ZIKV infection and wherein the subject is selected from the group consisting of a pregnant woman who has been exposed to ZIKV, or who has been bitten by a

mosquito suspected of harboring the ZIKV, a woman who lives in an area that has a ZIKV outbreak, or is visiting an area that has a ZIKV outbreak and who is considering conceiving a child, an immunocompromised individual, a person who is suspected of having been exposed to a person harboring the ZIKV, a person who comes into physical contact or close physical proximity with an infected individual, a hospital employee, a pharmaceutical researcher, maintenance personnel responsible for cleaning a hospital facility or institution where a ZIKV patient has been treated, individuals who have visited or are planning to visit an area or country known to have or suspected to have an outbreak of ZIKV, or a country known to have mosquitoes harboring the ZIKV.

41. The use of claim 36, wherein the medicament is for administration in combination with a second therapeutic agent, wherein the second therapeutic agent is selected from the group consisting of an anti-viral drug, an anti-inflammatory drug (*e.g.* corticosteroids and non-steroidal anti-inflammatory drugs), a different antibody to ZIKV, a vaccine for ZIKV, an immunomodulator and an interferon.

42. The method of claim 36, wherein the medicament is for administration subcutaneously, intravenously, intradermally, intramuscularly, intranasally, or orally.

43. Use of at least one antibody or antigen-binding fragment of any one of claims 1-11 in the manufacture of a medicament for decreasing the likelihood of transmitting ZIKV to the fetus of a pregnant female or prevention of transmission to the male reproductive organs.

44. The use of claim 43, wherein the medicament comprises a mixture of at least two anti-ZIKV antibodies, wherein the at least two anti-ZIKV antibodies comprise the HCVR/LCVR amino acid sequence pairs of SEQ ID NOs: 114/122 and 258/266.

45. The use of claim 43, wherein the medicament is for administration prophylactically or therapeutically to a subject in need thereof.

46. The use of claim 43, wherein the medicament is for administration in combination with a second therapeutic agent, wherein the second therapeutic agent is selected from the group consisting of an anti-viral drug, an anti-inflammatory drug (*e.g.* corticosteroids

and non-steroidal anti-inflammatory drugs), a different antibody to ZIKV, a vaccine for ZIKV, an immunomodulator, and an interferon.

47. The use of claim 46, wherein the medicament is for administration subcutaneously, intravenously, intradermally, intramuscularly, intranasally, or orally.

48. The antibody or antigen-binding fragment of any one of claims 1-13 for use in neutralizing infectious ZIKV by enhancing protection of the cell from virus infection, or from cell death.

49. The antibody or antigen-binding fragment for use of claim 48, which neutralizes infectious ZIKV having a wild type E protein, wherein the wild type E protein has a serine at position 302 of SEQ ID NO: 376, a threonine at position 311 of SEQ ID NO: 376, and a lysine at position 369 of SEQ ID NO: 376, but will not neutralize an infectious ZIKV having a mutated form of the E protein, wherein the mutated form of the E protein contains one or more of the following changes: a phenylalanine at position 302 of SEQ ID NO: 376, an isoleucine at position 311 of SEQ ID NO: 376, or a glutamic acid at position 369 of SEQ ID NO: 376.

50. The antibody or antigen-binding fragment for use of claim 48, wherein the enhanced protection is observed when the antibody is used alone, or when it is used in combination with one or more additional therapeutic agents or anti-ZIKV treatment modalities, wherein the one or more additional therapeutic agents is selected from the group consisting of an anti-viral drug, an anti-inflammatory drug (*e.g.* corticosteroids and non-steroidal anti-inflammatory drugs), one or more different anti-ZIKV antibodies, a vaccine for ZIKV, an immunomodulator and an interferon.

51. The antibody or antigen-binding fragment of any one of claims 1-13 for use in preventing, treating or ameliorating at least one symptom of ZIKV infection, or of decreasing the frequency or severity of at least one symptom of ZIKV infection in a subject in need thereof.

52. The antibody or antigen-binding fragment for use of claim 51, wherein the at least one symptom is selected from the group consisting of fever, headache, arthralgia, myalgia and a maculopapular rash.

53. The antibody or antigen-binding fragment for use of claim 51 that is for administration prophylactically or therapeutically to the subject in need thereof.

54. The antibody or antigen-binding fragment for use of claim 51, wherein the subject in need thereof is at risk for exposure to, or for acquiring a ZIKV infection and wherein the subject is selected from the group consisting of a pregnant woman who has been exposed to ZIKV, or who has been bitten by a mosquito suspected of harboring the ZIKV, a woman who lives in an area that has a ZIKV outbreak, or is visiting an area that has a ZIKV outbreak and who is considering conceiving a child, an immunocompromised individual, a person who is suspected of having been exposed to a person harboring the ZIKV, a person who comes into physical contact or close physical proximity with an infected individual, a hospital employee, a pharmaceutical researcher, maintenance personnel responsible for cleaning a hospital facility or institution where a ZIKV patient has been treated, individuals who have visited or are planning to visit an area or country known to have or suspected to have an outbreak of ZIKV, or a country known to have mosquitoes harboring the ZIKV.

55. The antibody or antigen-binding fragment for use of claim 51 that is for administration in combination with a second therapeutic agent, wherein the second therapeutic agent is selected from the group consisting of an anti-viral drug, an anti-inflammatory drug (*e.g.* corticosteroids and non-steroidal anti-inflammatory drugs), a different antibody to ZIKV, a vaccine for ZIKV, an immunomodulator and an interferon.

56. The antibody or antigen-binding fragment for use of claim 51 that is for administration subcutaneously, intravenously, intradermally, intramuscularly, intranasally, or orally.

57. The antibody or antigen-binding fragment of any one of claims 1-13 for use in decreasing the likelihood of transmitting ZIKV to the fetus of a pregnant female or preventing transmission to the male reproductive organs.

58. The antibody or antigen-binding fragment for use of claim 57, wherein the use comprises a mixture of at least two anti-ZIKV antibodies, wherein the at least two anti-ZIKV

antibodies comprise the HCVR/LCVR amino acid sequence pairs of SEQ ID NOs: 114/122 and 258/266.

59. The antibody or antigen-binding fragment for use of claim 57 that is for administration prophylactically or therapeutically to a subject in need thereof.

60. The antibody or antigen-binding fragment for use of claim 57 that is for administration in combination with a second therapeutic agent, wherein the second therapeutic agent is selected from the group consisting of an anti-viral drug, an anti-inflammatory drug (*e.g.* corticosteroids and non-steroidal anti-inflammatory drugs), a different antibody to ZIKV, a vaccine for ZIKV, an immunomodulator, and an interferon.

61. The antibody or antigen-binding fragment for use of claim 60 that is for administration subcutaneously, intravenously, intradermally, intramuscularly, intranasally, or orally.